The news today that DSM Biologics and Crucell N.V. had again scaled up production of the PER.C6 cell line was another sign that biopharma cell culture capacity concerns are (probably) a thing of the past, and that PER.C6 represents a breakthrough.
At the American Chemical Society national conference last weekend, Rensselaer Polytechnic researcher Dr. Robert Linhart announced that his team may have built the first fully synthetic heparin. Whether or not you believe that the possibility of another contamination crisis of natural raw heparin exists, the potential for a heparin supply...
A large push by Las Vegas economic development authorities to lure biotech companies away from New Jersey, California, and other hotbeds has by and large failed. The promise of tax incentives and cheap land for development means little, it seems, if the local biotech talent pool is dry.
Fierce Vaccines just spotlighted an article from this week's Scientific American, on a clinical trial of a vacccine for non Hodgkins lymphoma, which was derived by tobacco plants. Researchers produced tumor-fighting antigen within the plants by first extracting the gene coding for the antigen from white blood cells in patients'...
Just discovered the "PCR Song," which predates the Agilent video...with a "we are the world" theme. High school biotech students are also flooding YouTube with Biotech rap new dance forms...and this rather creative DNA Replication Song. Lots of fun (but hope they didn't submit these as their senior projects....)
This article from Wired News asked whether Mr. Schwarzenegger is advancing biotechnology quite as much as he claimed to be in his BIO speech last week. At issue: cease-and-desist letters sent to genetic testing companies.
Spoke briefly with one, Michael Kowolenko, SVP of biopharmaceutical manufacturing at Wyeth, who talked about the industry’s fear of change, why it exists and offered some suggestions on what to do about it. Below are some (raw) audio snippets of the interview.
That's how Control magazine's executive editor Jim Montague described the pharmaceutical industry in a recent and very memorable op-ed (read it here), in which he interviews experts including E-55 insider Gawayne Mahboubian-Jones. Jim brings to the the "so what" detachment of one who has covered PAT and process control as...
Geez Louise, could the pharma employment picture get much bleaker? On Friday, Schering-Plough announced it would cut 10% of its 55,000 global employees within the next two years, and that the company's Kenilworth, N.J. headquarters would feel the most pain.
This is pretty old news, but it certainly took me by surprise. Just glanced at the online masthead and the byline of an article from the November 2007 issue of Biopharm International and learned that Dr. Hussain has moved from Sandoz to... Philip Morris International? (OK.